David Lally, MD: Efficacy of Oral APX3330 for Diabetic Retinopathy

Presented at ASRS 2023, results from the phase 2 ZETA-1 trial showed oral APX3330 missed its primary endpoint, but the consideration of a binocular treatment effect may warrant further clinical development.

Related Keywords

United States ,American ,David Lally ,American Society Of Retina Specialists ,American Society ,Retina Specialists ,Annual Meeting ,Retina Research Institute ,New England Retina Consultants ,